OUR PRODUCTS
Each extended-release capsule contains 20 mg phenylephrine hydrochloride and 5 mg loratadine.
- Hypersensitivity to the components of the formulation, patients on treatment with MAO inhibitors, patients with narrow-angle glaucoma, urinary retention, severe hypertension, severe coronary artery disease and hyperthyroidism, constrictive peptic ulcer and diabetes.
- Ketoconazole, cimetidine, and erythromycin: Concomitant use increases loratadine concentrations.
- Beta-blockers: increase the vasoconstriction caused by phenylephrine.
- Oxytocin, an MAO inhibitor: prolongs and intensifies the pressure caused by phenylephrine.
- Antihistamines should be discontinued approximately 4 days prior to skin testing procedures as these medications may prevent or reduce potentially positive reactions to skin reaction indicators.
- It is used in the treatment of symptoms of allergic rhinitis, nasal congestion and itching of the nose.
Dosage:
- Adults and children over 12 years old: 1 capsule every 12 hours
- Hepatic impairment: A lower dose should be given initially, since the clearance of loratadine is slower.
- Half the recommended dose is recommended as an initial dose.
Fatigue, headache, drowsiness, dry mouth, skin rash, nausea, gastritis, rarely hair loss, high blood pressure in the elderly, bradycardia, palpitations, insomnia and anxiety.